Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock Has Consensus Target Price of $27.14 According to Brokerages

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) has been given an average recommendation of “Buy” by the eleven analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $27.14.

A number of research analysts have recently issued reports on ZVRA shares. Citizens Jmp lifted their price target on Zevra Therapeutics from $25.00 to $28.00 and gave the company a “market outperform” rating in a report on Thursday, August 6th. Wall Street Zen upgraded shares of Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. UBS Group reaffirmed a “buy” rating on shares of Zevra Therapeutics in a research report on Thursday, August 20th. Citigroup reiterated an “outperform” rating on shares of Zevra Therapeutics in a research note on Thursday, August 6th. Finally, William Blair raised shares of Zevra Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd.

Zevra Therapeutics Stock Performance

Shares of ZVRA opened at $11.17 on Monday. The company has a 50 day moving average price of $11.10 and a 200-day moving average price of $10.76. Zevra Therapeutics has a fifty-two week low of $8.01 and a fifty-two week high of $15.03. The stock has a market capitalization of $663.27 million, a PE ratio of 9.39 and a beta of 1.01.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.14. The company had revenue of $39.66 million for the quarter, compared to analyst estimates of $33.88 million. Zevra Therapeutics had a net margin of 52.80% and a return on equity of 57.91%. Equities research analysts forecast that Zevra Therapeutics will post 0.72 EPS for the current year.

Key Zevra Therapeutics News

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Q3 2026 revenue rose 45% year over year to $37.8 million, including $34.0 million from MIPLYFFA. Earnings also beat analyst estimates, and the company marked a fourth consecutive quarterly earnings beat. Zevra Q3 financial results and corporate update Zevra beats Q3 estimates for fourth straight quarter
• Positive Sentiment: Zevra expects to file a supplemental new drug application for MIPLYFFA in Q1 2027, a potential future growth opportunity. Zevra anticipates filing MIPLYFFA sNDA in Q1 2027
• Neutral Sentiment: A European CHMP opinion on MIPLYFFA remains expected in Q4; the regulatory outcome is still pending. Regulatory timeline update

Insider Buying and Selling at Zevra Therapeutics

In other Zevra Therapeutics news, CEO Neil F. Mcfarlane sold 20,000 shares of Zevra Therapeutics stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $11.25, for a total transaction of $225,000.00. Following the completion of the sale, the chief executive officer owned 417,225 shares of the company’s stock, valued at approximately $4,693,781.25. The trade was a 4.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Corey Watton sold 12,300 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $11.25, for a total transaction of $138,375.00. Following the completion of the sale, the director directly owned 1,800 shares in the company, valued at $20,250. This trade represents a 87.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 3.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zevra Therapeutics

Large investors have recently made changes to their positions in the company. AIGH Capital Management LLC purchased a new stake in shares of Zevra Therapeutics during the first quarter worth about $11,184,000. Integrity Alliance LLC. acquired a new position in Zevra Therapeutics in the 3rd quarter valued at $10,292,000. Dimensional Fund Advisors LP lifted its holdings in Zevra Therapeutics by 259.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company’s stock valued at $5,168,000 after purchasing an additional 400,336 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its holdings in Zevra Therapeutics by 116.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company’s stock valued at $5,502,000 after purchasing an additional 206,543 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Zevra Therapeutics in the second quarter valued at about $2,846,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with significant unmet medical needs. The company combines traditional drug development with data science and patient-focused research to advance therapies for diseases that may have limited treatment options.

Zevra’s lead commercial product is MIPLYFFA (arimoclomol), which is approved in the United States for the treatment of neurological manifestations of Niemann-Pick disease type C in adults and children aged 2 years and older, in combination with miglustat.